TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11086300
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 2 lakh units of Vitamin A orally (experimental group)
Study: 1533259
Drug: Chlorthalidone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (50 mg/day)
Study: 3296295
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (breathing exercises emphasizing inspiration with forced expiration technique in gravity assisted positions)
Study: 3296295
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (breathing exercises with positive expiratory pressure alternating with forced expiration technique in gravity assisted positions)
Study: 3296295
Drug: Treatment C
Normalized name: Acne Treatment Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C (breathing exercises with positive expiratory pressure and forced expiration technique in sitting position)
Study: 30311825
Drug: α-Lipoic Acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-Lipoic Acid (7 mg/kg), Carnosine (6 mg/kg), Thiamine (1 mg/kg)
Study: 25123219
Drug: 7-day-week therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day-week therapy
Study: 18298358
Drug: Circuit class
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circuit class therapy
Study: 15516351
Drug: Levobupivacaine 0.5%
Normalized name: levobupivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.5% plus 0.150 mg of clonidine
Study: 15516351
Drug: Levobupivacaine 0.5%
Normalized name: levobupivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.5% plus 1 ml of NaCl 0.9% (Control)
Study: 15516351
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% plus 0.150 mg of clonidine
Study: 15516351
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% plus 1 ml of NaCl 0.9% (Control)
Study: 12806381
Drug: Leuprorelin acetate
Normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin acetate (6-monthly injections)
Study: 12806381
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate (6-monthly injections)
Study: 2053506
Drug: Bromocriptine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (15 mg daily) - simplified three-step regimen
Study: 2053506
Drug: Bromocriptine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (15 mg daily) - standard seven-step regimen
Study: 2053506
Drug: Bromocriptine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (15 mg daily) - both regimens
Study: 6336981
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (CMF)
Study: 6336981
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (CMF plus T)
Study: 30958066
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg/kg/BM)
Study: 25005467
Drug: IV abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV abatacept (10 mg/kg) plus methotrexate (MTX)
Study: 21816029
Drug: RTS,S/AS01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 vaccine with booster dose of RTS,S/AS01
Study: 21816029
Drug: RTS,S/AS01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 vaccine with control vaccine at time of booster
Study: 21816029
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine at time of primary vaccination and booster
Study: 19947263
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus medicine group
Study: 18630549
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine group
Study: 17713976
Drug: Vildagliptin 25mg
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin 25mg intravenous infusion
Study: 15733479
Drug: Nimodipine infusion
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine infusion (20 microg.kg(‐1).h(‐1))
Study: 15733479
Drug: Nimodipine infusion
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine infusion
Study: 11999816
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin (CA)
Study: 11999816
Drug: Ticlopidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine plus aspirin (TA)
Study: 7886396
Drug: L-tryptophan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (50 mM, pH 5.7)
Study: 7886396
Drug: L-tryptophan and
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-tryptophan and D-tryptophan (50 mM, pH 5.7)
Study: 2896402
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg acetylsalicylic acid
Study: 2896402
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg acetylsalicylic acid
Study: 9973007
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg atenolol
Study: 27058906
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 supplementation (4,000 IU [100 μg] daily)
Study: 25027749
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received all standard ICU therapies
Study: 23022759
Drug: LMWH-nadroparin calcium
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH-nadroparin calcium (0.3 or 0.4 mL sc) administered 2 hours before surgery
Study: 23022759
Drug: Nadroparin calcium
Normalized name: nadroparin calcium
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin calcium administered daily post-surgery
Study: 12585970
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose regimen of cotrimoxazole
Study: 12585970
Drug: Escalating dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating dose regimen of cotrimoxazole starting with 75 mg/day, doubled every 48 hours
Study: 7018361
Drug: Amiloride/Hydrochlorothiazide (A/HCTH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride/Hydrochlorothiazide (A/HCTH) combination
Study: 24041733
Drug: Four sessions
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four sessions of birth and parent preparation in small groups
Study: 22028163
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy for four weeks
Study: 11174772
Drug: Patch angioplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch angioplasty
Study: 8763180
Drug: Patch closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch closure
Study: 28327693
Drug: Single visit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single visit treatment
Study: 28327693
Drug: Two visits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two visits with 1-week intracanal calcium hydroxide medication
Study: 23708174
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg and Placebo
Study: 21513721
Drug: Single s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single s.c. injection of ghrelin under cold exposure in mice
Study: 21513721
Drug: Four-hour intravenous
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-hour intravenous ghrelin infusion in healthy humans
Study: 10619348
Drug: Zileuton 600
Normalized name: zileuton 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton 600 mg po QID for 6 weeks
Study: 29558784
Drug: Alogliptin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin (25 mg/daily)
Study: 29558784
Drug: Gliclazide extended‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide extended‐release (30 mg/daily for HbA1c 7.5‐8.0% and 60 mg/daily for HbA1c 8.0‐8.5%)
Study: 20845002
Drug: Flavocoxid (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavocoxid (500 mg twice daily)
Study: 11146706
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg twice daily)
Study: 26215702
Drug: G‐Cem Automix
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐Cem Automix cement
Study: 26215702
Drug: G‐Cem Automix
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐Cem Automix cement at 37°C
Study: 1670723
Drug: Intensified chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified chemotherapy
Study: 12849773
Drug: Executive tasks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Executive tasks administered to children with Klinefelter's syndrome (KS)
Study: 30150464
Drug: Single i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single i.v. doses of 0.1 to 3 mg/kg of body weight
Study: 30150464
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg q24h over 60 min
Study: 30150464
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg q12h over 60 min
Study: 12496225
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (Control)
Study: 10691270
Drug: Triple regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple regimen (senna syrup, Picolax, Klean Prep)
Study: 9071429
Drug: Thalidomide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (200 mg/day orally for 28 days)
Study: 9071429
Drug: Thalidomide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (300 mg/day for an additional month)
Study: 9071429
Drug: Prednisone (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (for the patient who failed thalidomide therapy)
Study: 20698927
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (placebo)
Study: 31728618
Drug: CCRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCRT with PG2 injection (Astragalus polysaccharides) administered three times per week
Study: 31728618
Drug: CCRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCRT with PG2 injection
Study: 30396454
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (7-day dosage)
Study: 30396454
Drug: Long-acting GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting GnRH agonist (single dose)
Study: 18783399
Drug: Bortezomib 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.0 mg/m²
Study: 18783399
Drug: Bortezomib 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.3 mg/m²
Study: 20306195
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses (1.0 and 1.3 mg/m²)
Study: 16552342
Drug: Ximelagatran 36
Normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran 36 mg orally twice daily
Study: 16552342
Drug: Warfarin dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0
Study: 12666712
Drug: Immediate Functional
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Functional Loading (IFL) for 422 implants
Study: 12666712
Drug: Immediate Non-Functional
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Non-Functional Loading (INFL) for 224 implants
Study: 11967788
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (AT(1)-receptor blocker)
Study: 29110675
Drug: Lactoferrin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin and lysozyme daily supplement
Study: 20191582
Drug: Abatacept (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (10 mg/kg administered intravenously every 4 weeks)
Study: 15793107
Drug: micafungin (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: micafungin (12.5 to 200 mg/day)
Study: 7897962
Drug: prophylactic medication
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: prophylactic medication (levobunolol, acetazolamide, apraclonidine)
Study: 811704
Drug: Cyclandelate (Cyclospasmol),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclandelate (Cyclospasmol), 400 mg four times daily
Study: 25338498
Drug: rRT+APG101 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: rRT+APG101 (400 mg weekly i.v.)
Study: 17513803
Drug: 13-cis-retinoic acid
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 13-cis-retinoic acid (1 mg/kg/d orally) plus interferon alfa (3 x 10(6) U subcutaneously three times per week)
Study: 25223173
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no adjuvant therapy)
Study: 15078261
Drug: Amodiaquine (AQ)
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amodiaquine (AQ) 10 mg/kg
Study: 15078261
Drug: Artesunate (AR)
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate (AR) 4 mg/kg first day then half dose
Study: 11771678
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (250 mg to 2,000 mg over 10 weeks)
Study: 7519567
Drug: Chlormadinone acetate
Normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormadinone acetate (CMA) 25 mg
Study: 7519567
Drug: Acetazolamide (ACET)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (ACET) 250 mg
Study: 2657616
Drug: Amikacin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin (800 mg/m2/day) and ticarcillin‐clavulanate
Study: 2657616
Drug: Vancomycin (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (1.2 g/m2/day), amikacin, and ticarcillin
Study: 31987235
Drug: Foot reflexology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot reflexology applied twice a week for 6 weeks (30-40 min per session)
Study: 31500422
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 mg orally (days 1-4) + ondansetron 8 mg IV + dexamethasone 20 mg IV (30 minutes before chemotherapy) + dexamethasone 10 mg orally (days 1-4)
Study: 31500422
Drug: Placebo (days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (days 1-4) + ondansetron 8 mg IV + dexamethasone 20 mg IV (30 minutes before chemotherapy) + dexamethasone 10 mg orally (days 1-4)
Study: 23800177
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination therapy (polypill)
Study: 22760901
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate IV infusion (2 g)
Study: 22760901
Drug: Saline IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline IV infusion
Study: 19953931
Drug: Association of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of CD147 expression with depth of prostatic capsule invasion
Study: 16106594
Drug: Melagatran-ximelagatran (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melagatran-ximelagatran (subcutaneous melagatran for 1-2 days followed by oral ximelagatran for 6-9 days)
Study: 16106594
Drug: Ximelagatran (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran (oral for 7-12 days)
Study: 12021628
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg/day for 7 days
Study: 9807036
Drug: Tolrestat 200
Normalized name: tolrestat 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolrestat 200 mg/day
Study: 23297711
Drug: Amlodipine (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5-10 mg/day)
Study: 2405556
Drug: Captopril (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25-50 mg twice daily)
Study: 6212561
Drug: Alcohol-free benzoyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol-free benzoyl peroxide gel
Study: 31104962
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy initiated within 61 days
Study: 31104962
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy initiated after 61 days
Study: 25381429
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) at 375 mg/m² × 4
Study: 17095924
Drug: PRE-POST group
Normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRE-POST group (supplement consumed immediately before and after RE)
Study: 17095924
Drug: MOR-EVE group
Normalized name: Summer's Eve Medicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOR-EVE group (supplement consumed in the morning and late evening)
Study: 16931683
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac (60 mg)
Study: 8190480
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen (650 mg)
Study: 8190480
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (600 mg)
Study: 28222631
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml US‐TAP block (50 mg bupivacaine + 10 ml saline solution)
Study: 2669155
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 25 mg/day
Study: 12351281
Drug: mexiletine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: mexiletine 600 mg/d
Study: 3281307
Drug: Terbutaline 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 0.5 mg (0.5 ml)
Study: 31298171
Drug: Computerized cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized cognitive remediation therapy (CCRT)
Study: 19117153
Drug: Lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 8 mg administered PO
Study: 19117153
Drug: Lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 8 mg administered IM
Study: 19117153
Drug: Lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 8 mg administered IV
Study: 17006858
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of bromazepam (B3)
Study: 17006858
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of bromazepam (B6)
Study: 15029039
Drug: C974P (0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: C974P (0.25% fluid carbomer gel)
Study: 15029039
Drug: C940 (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: C940 (conventional carbomer gel)
Study: 8897086
Drug: Tenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenolol (100 mg)
Study: 1509999
Drug: Intravenous flecainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous flecainide (2 mg/kg, maximum dose 150 mg)
Study: 24275120
Drug: Iron supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplements
Study: 31800425
Drug: Topical TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TXA (3.0 g administered 5 minutes before final tourniquet release)
Study: 31800425
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (1.0 g before tourniquet inflation and again 3 hours later)
Study: 23892922
Drug: Pegylated G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated G-CSF
Study: 23892922
Drug: Unpegylated G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unpegylated G-CSF
Study: 23892922
Drug: Three G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three G-CSF schedules (pegylated and unpegylated)
Study: 21350110
Drug: Aliskiren (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (150 mg force titrated to 300 mg daily after 3 months) plus losartan (100 mg)
Study: 31691621
Drug: Cimicifuga racemosa
Normalized name: CIMICIFUGA RACEMOSA ROOT
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimicifuga racemosa (160 mg dry extract with 4 mg of triterpene glycosides)
Study: 31116919
Drug: Nasal high-flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high-flow therapy and CPAP
Study: 19198022
Drug: PEG solution
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG solution and simethicone (Group 2)
Study: 19198022
Drug: PEG solution
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG solution (Group 1)
Study: 14719211
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of 2 drugs (rifampicin + cotrimoxazole or doxycycline)
Study: 14719211
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 3 drugs (streptomycin + rifampicin + doxycycline)
Study: 14719211
Drug: Treatment duration
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment duration of 5 months or less
Study: 14719211
Drug: Treatment duration
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment duration of more than 5 months
Study: 8821516
Drug: Placebo, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 3 times daily for 7 days